Aquestive Therapeutics’ (AQST) Buy Rating Reaffirmed at Wedbush

Wedbush reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report issued on Tuesday, TipRanks reports. Wedbush currently has a $31.00 target price on the stock.

Several other research analysts have also commented on AQST. Royal Bank of Canada restated a buy rating and issued a $8.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, March 25th. Zacks Investment Research lowered shares of Aquestive Therapeutics from a buy rating to a hold rating in a research note on Wednesday, June 3rd. Finally, HC Wainwright reiterated a buy rating and set a $15.00 price objective (up previously from $13.00) on shares of Aquestive Therapeutics in a research note on Friday, May 22nd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Aquestive Therapeutics has an average rating of Buy and a consensus price target of $14.67.

NASDAQ AQST opened at $4.86 on Tuesday. Aquestive Therapeutics has a one year low of $1.41 and a one year high of $10.00. The company’s 50 day moving average price is $5.35 and its 200 day moving average price is $4.36. The firm has a market capitalization of $168.92 million, a price-to-earnings ratio of -1.92 and a beta of 3.61.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.02). The company had revenue of $8.77 million for the quarter, compared to analysts’ expectations of $10.90 million. As a group, sell-side analysts anticipate that Aquestive Therapeutics will post -1.64 earnings per share for the current fiscal year.

In other news, CEO Keith J. Kendall sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $5.11, for a total transaction of $255,500.00. Following the completion of the sale, the chief executive officer now owns 638,964 shares of the company’s stock, valued at $3,265,106.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander Mark Schobel sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $3.70, for a total transaction of $148,000.00. Following the sale, the insider now directly owns 982,113 shares of the company’s stock, valued at approximately $3,633,818.10. The disclosure for this sale can be found here. Insiders have sold 170,000 shares of company stock worth $743,500 in the last quarter. Insiders own 42.58% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its position in shares of Aquestive Therapeutics by 60.8% during the first quarter. Tower Research Capital LLC TRC now owns 21,622 shares of the company’s stock worth $47,000 after buying an additional 8,172 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of Aquestive Therapeutics by 57.3% during the first quarter. Two Sigma Advisers LP now owns 17,300 shares of the company’s stock worth $38,000 after buying an additional 6,300 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Aquestive Therapeutics during the first quarter worth approximately $383,000. JPMorgan Chase & Co. grew its position in shares of Aquestive Therapeutics by 29.9% during the first quarter. JPMorgan Chase & Co. now owns 413,962 shares of the company’s stock worth $907,000 after buying an additional 95,381 shares in the last quarter. Finally, Oak Grove Capital LLC grew its position in shares of Aquestive Therapeutics by 369.3% during the first quarter. Oak Grove Capital LLC now owns 70,400 shares of the company’s stock worth $154,000 after buying an additional 55,400 shares in the last quarter. 52.68% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

See Also: What are municipal bonds?

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.